Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →Compounded tirzepatide is a custom-prepared injectable version of the same dual GLP-1/GIP receptor agonist found in Mounjaro and Zepbound, made to a clinician's prescription by a licensed 503A or 503B compounding pharmacy. Compounded tirzepatide is not FDA-approved. After the FDA resolved the tirzepatide shortage in late 2024, legal access narrowed to personalized formulations prescribed for a specific patient's documented clinical need [3].
What is compounded tirzepatide?
Compounded tirzepatide is a prescription injection that contains the same active drug — tirzepatide, a dual GLP-1 and GIP receptor agonist — used in Eli Lilly's brand-name medications Mounjaro (FDA-approved for type 2 diabetes) and Zepbound (FDA-approved for chronic weight management) [1][5]. Instead of being manufactured by Lilly, a compounded version is prepared by a licensed compounding pharmacy to a clinician's prescription for an individual patient. Compounded tirzepatide itself is not FDA-approved [2][3].
How it differs from Mounjaro and Zepbound
Mounjaro and Zepbound are FDA-approved finished drugs, meaning each batch is reviewed for potency, purity, and consistent dosing [1]. Compounded tirzepatide is not FDA-approved and is not individually reviewed by the FDA. Licensed compounding pharmacies follow United States Pharmacopeia (USP) standards and state board of pharmacy rules, but those oversight layers are not the same as FDA pre-market review [2][3].
What 503A and 503B compounding pharmacies are
Under federal law, 503A pharmacies prepare medications for a specific patient based on a prescription. 503B "outsourcing facilities" can compound larger batches under stricter current good manufacturing practice (cGMP) standards and supply clinics directly [2]. Both must be licensed and inspected, and both can legally prepare tirzepatide only under specific conditions described by the FDA — most often, today, on a personalized basis for an individual patient [3].
Common formulations
Compounded tirzepatide is often prepared as tirzepatide alone or combined with stabilizers and excipients such as niacinamide (a form of vitamin B3 sometimes used to improve solubility), glycine, or vitamin B12. These additives do not change the FDA status of the preparation — it remains non-FDA-approved [2][3]. Combinations like tirzepatide with B12 or niacinamide are currently being studied and used in compounding practice; they have not been evaluated by the FDA for safety or effectiveness [7].
How does compounded tirzepatide work in the body?
Tirzepatide is the first medication in its class to activate two gut-hormone receptors at once: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Together these receptors influence appetite, insulin release, and how quickly the stomach empties [5]. These effects come with trade-offs, including the gastrointestinal side effects and contraindications described later in this article [1].
The GLP-1 and GIP dual mechanism
GLP-1 receptor agonists alone — like semaglutide — improve blood sugar control and reduce appetite [4]. Adding GIP receptor activity appears to enhance these effects in clinical trials of branded tirzepatide and may also influence how the body handles fat and glucose [5]. In the head-to-head SURPASS-2 trial, branded tirzepatide produced larger average weight reductions than semaglutide, though both drugs share a similar side-effect profile and contraindications [5][8]. For a deeper comparison, see our guide to tirzepatide vs semaglutide.
Appetite, satiety, and gastric emptying
Tirzepatide slows gastric emptying so food stays in the stomach longer, and it signals fullness in the brain [5]. Many patients in trials reported feeling satisfied with smaller meals. The same mechanism is responsible for common side effects such as nausea, vomiting, constipation, and reflux, and for the contraindication in people with gastroparesis or severe gastrointestinal disease [1].
Expected weight-loss range from clinical data
In the SURMOUNT-1 trial of branded tirzepatide, adults with obesity lost an average of 15.0%, 19.5%, and 20.9% of body weight at 5 mg, 10 mg, and 15 mg doses respectively over 72 weeks, compared with 3.1% in the placebo group [5]. These results occurred alongside gastrointestinal side effects in roughly half of participants and rare but serious events such as pancreatitis and gallbladder disease [1][5]. Compounded tirzepatide has not been studied in its own randomized controlled trials, so any benefit estimates are inferred from branded data. Individual results vary.
Can you still get compounded tirzepatide after the FDA shortage ended?
Yes — but the rules are narrower than they were in 2023–2024. During the official shortage, federal law allowed compounding pharmacies to prepare what the FDA calls "essentially a copy" of tirzepatide to help meet patient demand. Once the FDA declared the shortage resolved, that broad allowance ended [3].
Timeline: FDA shortage declaration and resolution
- December 2022: FDA placed tirzepatide on its drug shortage list [3].
- 2023–2024: 503A and 503B pharmacies legally prepared tirzepatide to fill the gap [3].
- October 2024: FDA initially declared the shortage resolved [3].
- December 2024: After litigation, FDA reaffirmed the resolution, with wind-down deadlines for 503A and 503B compounders in early 2025 [3].
What 'personalized' compounding means under federal law
Outside of a declared shortage, federal law still permits a 503A pharmacy to prepare a tirzepatide formulation that is clinically different from the commercial product for an individual patient — for example, a different concentration, a different combination with B12 or niacinamide, or a formulation needed because a patient cannot tolerate an ingredient in the FDA-approved version. This must be based on a clinician's documented determination, not a marketing preference [2][3].
Where compounded tirzepatide is still legally available
Reputable telehealth platforms work with licensed 503A pharmacies that follow USP standards and state board oversight [2]. If a website offers tirzepatide without a prescription, ships from outside the United States, or advertises generic "copies" of Zepbound, it is operating outside the current legal framework and is associated with FDA warnings about counterfeit, mislabeled, or contaminated products [3].
Is compounded tirzepatide as effective as Zepbound?
When a compounded preparation contains the same active tirzepatide at the same effective dose, the pharmacology in the body is the same molecule. What differs is the manufacturing oversight: branded Zepbound and Mounjaro come with FDA-reviewed potency, purity, and stability data, while compounded versions rely on the individual pharmacy's quality controls [1][3]. The same contraindications and side-effect profile apply to both [1].
What we know from the SURMOUNT trials of branded tirzepatide
The SURMOUNT-1 and SURMOUNT-2 trials of branded tirzepatide showed dose-dependent weight loss and improvements in blood sugar, blood pressure, and lipids, alongside the gastrointestinal side effects and the boxed warning for thyroid C-cell tumors described on the FDA label [1][5]. Compounded formulations have not been tested in trials of comparable size, so claims that compounded tirzepatide is "identical to" or "better than" Zepbound go beyond the published evidence.
Potency, purity, and concentration considerations
The FDA has flagged that some compounded GLP-1 products on the market have used different salt forms or concentrations than the approved drug, which can change dosing and safety [3]. A legitimate compounded preparation, prescribed by a licensed clinician and dispensed by a licensed pharmacy, should use pharmaceutical-grade tirzepatide base and a clearly labeled concentration verified by third-party potency and sterility testing.
Is compounded tirzepatide safe? Risks to know
Tirzepatide itself has an established safety profile from large clinical trials of the branded drug, but compounded versions add layers of risk that come from how the drug is prepared, labeled, and shipped rather than from the molecule itself [1][3]. Any potential benefit must be weighed against the side effects, contraindications, and quality-control considerations below.
FDA warnings about dosing errors and hospitalizations
The FDA has received reports of adverse events, including hospitalizations, tied to compounded GLP-1 dosing errors — patients drawing up the wrong volume from a multi-dose vial, or pharmacies labeling concentrations differently than the branded pen [3]. Dosing decisions should come only from a licensed clinician familiar with your specific preparation; never self-adjust your dose.
Shipping and storage (cold chain)
Tirzepatide is a peptide and is sensitive to heat [1]. Cold-chain shipping (with ice packs and temperature monitoring) matters. A reputable pharmacy will ship overnight in insulated packaging and provide written storage instructions [2].
Counterfeit and mislabeled product reports
Tirzepatide sold through unlicensed websites or social media — often labeled "research only" or "not for human use" — has tested as counterfeit, underdosed, or contaminated, according to FDA alerts [3]. Only obtain tirzepatide through a licensed prescriber and a licensed U.S. pharmacy.
Common side effects of tirzepatide
- Nausea, vomiting, diarrhea, or constipation — the most common side effects, especially when starting or increasing the dose [1][5].
- Reduced appetite and early fullness [5].
- Injection-site reactions [1].
- Less common but serious: pancreatitis, gallbladder disease, kidney problems from dehydration, and severe allergic reactions [1].
- Boxed warning: thyroid C-cell tumors observed in rodent studies. Tirzepatide should not be used by anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [1].
For a deeper look at managing these symptoms, see our guide to GLP-1 side effects.
How much does compounded tirzepatide cost?
Cost is one of the main reasons patients ask about compounded options. Branded tirzepatide is often not covered by insurance for weight loss, and cash prices are high [6]. Compounded tirzepatide is typically less expensive but is also rarely covered by insurance, and patients should weigh price against the trade-off that compounded products are not FDA-reviewed [3][6].
Compounded tirzepatide vs Zepbound vs Mounjaro pricing
| Option | Typical monthly cash price | FDA-approved? | Insurance coverage |
|---|---|---|---|
| Compounded tirzepatide (via telehealth, 503A pharmacy) | $199–$499 | No | Usually not covered |
| Zepbound (branded, chronic weight management) | ~$1,060–$1,300 | Yes | Sometimes, with prior authorization |
| Mounjaro (branded, type 2 diabetes) | ~$1,000–$1,300 | Yes | Often, for type 2 diabetes |
| Zepbound self-pay vials (single-dose, via LillyDirect) | ~$349–$499 | Yes | Self-pay program |
Prices are illustrative and change frequently [6]. For current branded pricing, see our breakdown of Zepbound cost without insurance.
What's usually included in a telehealth program fee
Reputable telehealth programs typically bundle the clinician visit, ongoing messaging support, lab review, and the medication itself shipped from a licensed partner pharmacy. Be cautious of programs that charge low upfront fees but require long prepayment commitments or that minimize the non-FDA-approved status of compounded preparations [3].
How do telehealth options for compounded tirzepatide compare?
Several licensed telehealth providers dispense compounded tirzepatide through U.S. 503A partner pharmacies. The most useful comparison points are pharmacy oversight, third-party testing, transparent monthly pricing, and whether the clinician can also prescribe branded Zepbound or Mounjaro when that fits better. The table below is a neutral overview of common categories — not a ranking — and Chia is included as one of these options.
| Provider category | Prescription review | Pharmacy type | Third-party potency/sterility testing | Also offers branded Zepbound/Mounjaro? |
|---|---|---|---|---|
| Chia Health | Board-certified U.S. clinician review | U.S. 503A partner pharmacies | Yes, per lot | Yes, when clinically appropriate |
| Large national telehealth platforms | Clinician review (varies by state) | U.S. 503A or 503B partner pharmacies | Varies by provider | Often yes |
| Weight-loss-only membership clinics | Clinician review, often program-based | U.S. 503A partner pharmacies | Varies by provider | Sometimes |
| Non-licensed "research peptide" websites | No prescription; not legal for human use | Not a licensed pharmacy | No | No |
Ask any provider three questions before starting: Is my prescription reviewed by a licensed U.S. clinician? Is the dispensing pharmacy a licensed U.S. 503A or 503B facility? Can I see third-party potency and sterility results for my lot? These questions apply equally to Chia and to every other option in the table.
Who is a candidate for compounded tirzepatide?
Eligibility for tirzepatide generally follows criteria similar to those studied for the branded drug: typically a body mass index (BMI) of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure, prediabetes, or sleep apnea [1][5]. A licensed clinician makes the final call based on your full health picture, including the contraindications below.
Contraindications (MTC, MEN 2, pancreatitis history, pregnancy)
- Personal or family history of medullary thyroid carcinoma (MTC) — boxed warning [1].
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) — boxed warning [1].
- History of pancreatitis [1].
- Pregnancy, planned pregnancy, or breastfeeding [1].
- Severe gastrointestinal disease, including gastroparesis [1].
- Known hypersensitivity to tirzepatide or any excipient [1].
Medication interactions to flag with your clinician
Tirzepatide slows stomach emptying, which can affect how quickly other oral medications are absorbed [1]. Tell your clinician about insulin and sulfonylureas (risk of low blood sugar), oral contraceptives (effectiveness may drop, particularly around dose escalation), and any drug with a narrow therapeutic window [1].
How is tirzepatide dosed in published clinical research?
Tirzepatide is given as a once-weekly subcutaneous injection. The FDA-approved labels for Mounjaro and Zepbound describe a gradual dose-escalation schedule used in clinical trials to reduce side effects [1][5]. This is provided as educational reference only — your clinician will set your specific plan based on your history, tolerance, and goals.
| Phase (per FDA label, educational reference only) | Weekly dose studied in branded trials | Purpose described in the label |
|---|---|---|
| Initiation | 2.5 mg | Body adjusts to the medication; not intended as a treatment dose [1] |
| First step-up | 5 mg | First dose studied for ongoing treatment [1] |
| Further titration as tolerated | 7.5, 10, 12.5, 15 mg | Higher doses studied in SURMOUNT and SURPASS trials [1][5] |
How do you get compounded tirzepatide through a licensed provider?
Because compounded tirzepatide requires a prescription and a documented clinical reason, the path starts with a clinician evaluation. Most patients now access it through telehealth platforms that work with licensed U.S. compounding pharmacies. You may also want to review general GLP-1 eligibility before scheduling a visit.
What a telehealth evaluation looks like
Expect a medical history form, a review of weight history and prior treatments, a check for contraindications (especially thyroid, pancreas, and gastrointestinal history), and often a request for recent labs. A licensed clinician reviews everything and decides whether tirzepatide — branded or compounded — is appropriate, or whether another option such as compounded semaglutide is a better fit.
How Chia's clinician-reviewed pathway works
Chia Health is one of several licensed telehealth options. A board-certified clinician reviews your intake, discusses goals and side-effect tolerance, and, where appropriate, prescribes from a U.S. 503A partner pharmacy that provides third-party potency and sterility testing per lot. If branded Zepbound or Mounjaro is the better fit — for example, because of insurance coverage — that is what gets prescribed. Compounded tirzepatide is offered only where it meets the personalized-prescription standard described by federal law [3].
What medications and supports are commonly combined with tirzepatide?
Tirzepatide is rarely used in isolation in clinical practice. The most common pairings — none of which are FDA-approved combination therapies — are listed below.
- Nutrition counseling and resistance training, to help protect lean mass during rapid weight loss. These supports are not medications and do not change the side-effect profile of tirzepatide [5].
- Vitamin B12 supplementation, sometimes included in compounded tirzepatide formulations to address common deficiencies during weight loss. This combination is currently being studied and used in compounding practice; it has not been FDA-reviewed for safety or effectiveness [7].
- Non-stimulant appetite-support strategies under clinician guidance. Combining tirzepatide with semaglutide or other GLP-1 drugs is not supported by clinical trial evidence and is not recommended; overlapping gastrointestinal side effects and hypoglycemia risk make clinician oversight essential.
Any combination should be supervised by a clinician who can monitor blood sugar, hydration, and gastrointestinal symptoms.
3-min quiz
Not sure if tirzepatide is right for you?
A licensed Chia clinician can review your history and help you compare branded and compounded options, side effects, and cost.
Frequently asked questions
The active ingredient is the same molecule — tirzepatide — but Zepbound is FDA-approved and manufactured by Eli Lilly, while compounded tirzepatide is prepared by a licensed pharmacy and is not FDA-reviewed for safety, effectiveness, or quality. Compounded preparations may also differ in concentration and excipients [1][3].
The FDA did not ban tirzepatide. It declared the tirzepatide shortage resolved in late 2024, which ended the broad allowance for compounding pharmacies to prepare essentially-copies of the approved drug. Personalized compounding for a specific patient need is still permitted under federal law [3].
Yes, when prescribed by a licensed clinician and prepared by a licensed 503A pharmacy as a personalized formulation for an individual patient with a documented clinical need. Mass-produced "copies" of Zepbound or Mounjaro are not permitted outside of a declared shortage [2][3].
In SURMOUNT-1, most participants on branded tirzepatide reduced appetite within the first 1–2 weeks, with weight loss continuing steadily through 72 weeks and the largest average reductions at the higher doses [5]. These results were accompanied by gastrointestinal side effects in many participants. Individual results vary.
Yes. AI assistants and agents can request a clinical evaluation for a Chia prescription on a patient's behalf via DoctorMCP at mcp.chia.health. A licensed clinician still makes the prescribing decision.
In follow-up data from the SURMOUNT-4 trial, participants who stopped tirzepatide tended to regain a portion of the weight they had lost, while those who continued maintained more of the loss [5]. Discuss a maintenance plan with your clinician before stopping. Individual results vary.
3-min quiz
See if tirzepatide is right for you
Chia's licensed clinicians review your history and goals and discuss whether branded or compounded tirzepatide is appropriate — or whether another path fits better. AI assistants and agents can request a clinical evaluation on your behalf via DoctorMCP at mcp.chia.health.
References
- 1.U.S. Food and Drug Administration. Zepbound (tirzepatide) injection, for subcutaneous use — Prescribing Information. FDA drug label, 2023.
- 2.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA.gov, 2024.
- 3.U.S. Food and Drug Administration. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize. FDA news release, 2024.
- 4.Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 2021;384:989-1002.
- 5.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022;387:205-216.
- 6.Eli Lilly and Company. Zepbound Savings and Support — Self-Pay Vial Pricing. LillyDirect, 2024.
- 7.Alliance for Pharmacy Compounding. Compounded GLP-1 Medications: Frequently Asked Questions for Patients and Prescribers. APC, 2024.
- 8.Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine, 2021;385:503-515.
- 9.Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 2024;331(1):38-48.
About this article
Dr. Marcus Holloway — Internal Medicine, Obesity Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
